1050 ET - Novo Nordisk's headline phase 1 results for amycretin are highly encouraging, Deutsche Bank analyst Emmanuel Papadakis writes. Amycretin is potentially instrumental to the investment case, and thus the results are a clear minor positive, he adds. Deutsche Bank continues to believe the disappointment over CagriSema's initial headline results is overdone, and hence the subsequent derating is a clear buying opportunity. The bank rates Novo Nordisk at buy with a 900 Danish kroner target price. Shares trade 1.8% lower following Friday's strong rally on the news. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
January 27, 2025 10:50 ET (15:50 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。